Quoin Pharmaceuticals (NASDAQ:QNRX) announced on Wednesday that the U.S. Food and Drug Administration has granted Fast Track Designation to its QRX003 lotion (4%), a topical therapy aimed at treating Netherton Syndrome.
The rare, life-threatening genetic disorder currently has no FDA-approved treatments, placing Quoin at the forefront of a specialized market.
The Fast Track status is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill unmet medical needs.
This designation will allow Quoin to engage in more frequent communication with the FDA and may provide eligibility for Accelerated Approval and Priority Review, should the clinical data support such pathways.
QRX003 is currently undergoing evaluation in two late-stage, whole-body clinical trials.
The therapeutic candidate had already secured a robust regulatory moat, having previously received Orphan Drug and Pediatric Rare Disease designations from both the FDA and the European Medicines Agency (EMA).
Netherton Syndrome is characterized by chronic skin inflammation, severe dehydration, and high risk of infection.
By targeting the underlying protease imbalance associated with the disease, Quoin’s 4% lotion aims to restore skin barrier function.